- Clinical Trials
- Research News
- Industry Trends
- Agency Actions
- Drug Safety Issues
- Approvals, Launches, & New Indications
- Health Care Reform
New Antibiotic Shows Promise for Treating MRSA Pneumonia
Patients respond well to ceftaroline fosamil (September 11)
A drug approved 2 years ago for treating bacterial infections may hold promise for treating potentially fatal methicillin-resistant Staphylococcus aureus (MRSA) pneumonia, according to a Henry Ford Hospital study.
Researchers found that patients treated with the antibiotic ceftaroline fosamil (CPT-F) had a lower mortality rate after 28 days compared with patients treated with vancomycin, the most common drug therapy for MRSA pneumonia.
In the retrospective study, 33 of 38 patients responded well to treatments of CPT-F and were discharged from the hospital after the infection cleared. Of the five patients who died, three of the deaths were attributed to other serious medical conditions.
The mortality rate for patients treated with vancomycin has been reported to be as high as 32% after 28 days. In the new study, the mortality rate for the CPT-F–treated patients was 13%.
The study’s findings were presented Sept. 11 at the annual Interscience Conference on Antimicrobial Agents and Chemotherapy, held in Denver.
Source: EurekAlert; September 11, 2013.